Navigation Links
Multiple in Biological Technology

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results

... our SPA for the Phase 3 trial of perifosine in multiple myeloma. We look forward to finalizing our ... is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under SPA, pending commencement. Keryx ...

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

... (KRX-0401), in relapsed or relapsed/refractory multiple myeloma patients previously treated with ... Combination of Bortezomib and Dexamethasone in multiple Myeloma Patients Previously Treated with ... 400 patients with relapsed or relapsed/refractory multiple myeloma. The primary endpoint is progression-free ...

Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing

... on initiating a Phase I clinical trial for multiple myeloma. Pursuant to the respective ... of these transactions to further advance its multiple myeloma research and development program with the ... of SNS-101 as a novel treatment alternative for multiple myeloma," said Allen Cato, MD, PhD, CEO of Cato ...

Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference

... targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts ... and small molecule compounds directed at multiple high value cancer stem cell targets of a variety ... which the Company has utilized to identify multiple compounds that target and impair cancer stem ...

BioMS Medical announces second quarter 2009 results

... MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and ... dirucotide in patients with secondary progressive multiple sclerosis and with a positive outcome, our drug ... technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal ...

Intellikine Completes $51 Million Financing

... autoimmune diseases. The company has discovered multiple classes of proprietary compounds that are potent, ... TORC1/2 inhibitor, has demonstrated efficacy in multiple models of cancer and is expected to enter Phase I ... autoimmune diseases. Intellikine has discovered multiple classes of proprietary compounds that selectively ...

UCF team's advanced nerve cell system could help cure diabetic neuropathy, related diseases

... multiple sclerosis, diabetic neuropathy, and other ... nerves in a lab culture, among other advances. multiple sclerosis (MS), diabetic neuropathy, ... central nervous system motoneurons involved in multiple sclerosis, a goal preliminary experiments suggest ...

I Walk Because Program Gives Consumers a Voice

... friends, family, and other people living with multiple sclerosis, Saatchi & Saatchi Wellness ... to coincide with the 2009 season of the National multiple Sclerosis Society's WalkMS program, is the online ... to connect the actual walk experience across multiple media channels and create a meaningful way for ...

Springborn Deploys eStudy(TM) Hosted Solution for Management of Global Environmental Testing

... implement throughout its organization to manage multiple study types from protocol to report. With eStudy, ... , eNotebook design , collection of data from multiple sources, multiple users ...

Next Stage Solutions Announces Three New Financial Services For Emerging Business

... Next Stage Solutions team equips its clients with multiple game plans; a blue print for every contingency. ... Next Stage Solutions team equips its clients with multiple game plans; a blue print for every contingency. ... By contrast, the NSS team equips its clients with multiple game plans; a blueprint for every contingency. ...

Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association

... trials of carfilzomib for the treatment of multiple myeloma at the 14th Congress of the European ... malignancies and solid tumors. Relapsed multiple Myeloma Patients Achieve Responses with ... trial of single-agent carfilzomib in relapsed multiple myeloma patients. Patients in the study have ...

American Biotech Labs(R) Garners 2009 Utah Best of State Award

... independent judges. ABL products have received multiple U.S. and international patents and government ... SilverSol Technology, which has garnered multiple patents in the U.S. and countries throughout the ... The company's products have been the subject of multiple peer-reviewed articles in professional journals, ...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... (B) versus B alone in previously treated multiple myeloma (MM) (Abstract 8591) General Poster ... is indicated for the treatment of patients with multiple myeloma who have not previously received VELCADE ... myocardial injury In the randomized multiple myeloma study, 25 patients (8%) in the VELCADE ...

BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences

... MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Randy ... TITLE: "Dirucotide: A Potential Therapy for multiple Sclerosis" WHEN: Thursday June 4th at ... technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal ...

NIST's LIDAR may offer peerless precision in remote measurements

... built a laser ranging system that can pinpoint multiple objects with nanometer precision over distances ... including precision, rapid updates from multiple reference points at the same time, and minimal ... ambiguity." The system can update measurements to multiple targets simultaneously every 200 microseconds. ...

Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting

... Trials of Carfilzomib in Relapsed/Refractory multiple Myeloma and Advanced Solid Tumors Featured in ... that data from clinical trials of carfilzomib in multiple myeloma and advanced solid tumors will be ... accelerated approval study in relapsed/refractory multiple myeloma and Phase 2 clinical studies in ...

EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting

... orphan drug designation for ENMD-2076 for multiple myeloma. EntreMed Vice President and Chief ... with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ... activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 ...

BioMS Medical Announces First quarter 2009 results

... MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and ... dirucotide in patients with secondary progressive multiple sclerosis, in the second half of 2009," said ... for the treatment of secondary progressive multiple sclerosis." Currently, BioMS is conducting two ...

Senesco Technologies Reports Third Quarter Fiscal 2009 Financial Results

... finding studies in mice for SNS-01, the Company's multiple myeloma drug candidate. Management ... New Drug application for SNS-01, the Company's multiple myeloma drug candidate, before the end of ... human health programs, specifically the Company's multiple myeloma research program, which was partially ...

Under the Microscope: 'Micro IVF'

... only cut down on costs, but to diminish risks of multiple births. Following are the opinions expressed ... the possibility of embryo overproduction and multiple births. Minimal Stimulation IVF is currently ... minimizing their risk of complications such as multiple pregnancy, hyper-stimulation syndrome or ...

Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research

... Inc. (Nasdaq: KERX ) today announced multiple presentations of preclinical data highlighting ... induces synergistic anti-tumor activity in multiple myeloma (AACR Annual Meeting 2008, #4181). The ... is currently in Phase 2 clinical development for multiple tumor types. The Company is also engaged in ...

Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team

... proteasome inhibitor for the treatment of multiple myeloma and other cancers, through late-stage ... proteasome inhibitors, and is currently in multiple Phase 2 clinical studies to evaluate its safety and efficacy in multiple myeloma and other malignancies. Proteolix is ...

BioMS Medical Announces 2008 Year End Results

... MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and ... in patients with secondary progressive multiple sclerosis." Currently, BioMS is conducting two ... technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal ...

Agencies Unite to Launch Donor Network Alliance: First-Ever Web-Based Collective of Egg Donor Candidates

... consolidated source of egg donors recruited by multiple agencies across the United States. ... "This helps them avoid excessive research of multiple agencies, tracking multiple usernames and passwords, and ...

ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability

... trial professionals can: Aggregate multiple studies into a program/portfolio view or ... re-keying involved with manually rolling up multiple study plans into program- or company-wide ... dimension to: Compare portfolios for multiple long-range planning scenarios Assign ...

Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer

... potential to become a platform product addressing multiple indications, combinations and formulations for ... and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity ... chemotherapy drugs. It is being studied in multiple cancer indications, treatment combinations and by ...

Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results

... finding studies in mice for SNS-01, the Company's multiple myeloma drug candidate. Senesco's data ... Vitro and in Vivo". Senesco's preclinical multiple myeloma data was presented at the 20th ... human health programs, specifically the Company's multiple myeloma research program, which was partially ...

BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis

... MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results from ... Expanded Disability Status Scale (EDSS) and the multiple Sclerosis Functional Composite (MSFC) score. The ... being investigated for the potential treatment of multiple sclerosis (MS), an autoimmune disease caused by ...

You Want To Have a Baby...But Not Eight

... multiple births can be avoided ATLANTA, Jan. 30 ... in California, the message to them is that multiple births can be prevented with today's advanced ... at our clinic on the risks associated with multiple births and how such births can be avoided." ...

Omnitura Therapeutics Announces Private Placement Financing

... a $24 million private placement agreement with multiple closings. Under the terms of this financing, ... oncology drugs. MFMT(TM) drugs possess multiple therapeutic functions and act upon multiple biological targets to treat complex chronic ...

International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"

... Freelite(TM) in the diagnosis and management of multiple myeloma, a cancer of cells in the bone marrow, ... Site, used for the diagnosis and monitoring of multiple myeloma (MM) and related disorders. ... of our product in the diagnosis and treatment of multiple myeloma and other plasma cell disorders. Not ...

Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

... potential to become a platform product addressing multiple indications, combinations and formulations. The ... and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity ... chemotherapy drugs. It is being studied in multiple cancer indications, treatment combinations and in ...

Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer

... therapeutic in mid-stage development for multiple oncology indications. The study, entitled "A ... in San Francisco and represents the first of multiple new clinical trials for this innovative therapy ... About AEG35156 Cancer cells acquire multiple mutations that disable their normal response to ...

Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System

... manufacturing protein-based therapeutics, and to multiple sales within the same organization." ... holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, ... manufacturing protein-based therapeutics, sell multiple instruments within the same organization, and to ...

Nikon Instruments A1 Confocal Laser Microscope Series With NIS-Elements C Software Delivers Fully Integrated Comprehensive Confocal Imaging Capabilities

... 3.25 gigabyte limit of 32bit operating systems. multiple acquisition modalities, including the control of ... of rapid Piezo stage Z-axis focus for acquiring multiple Z-axis image stacks. Together, these features ... and rotations, automated object counting and multiple binary layer thresholding and processing. ...

WellCentive Launches New Health Information Exchange Platforms

... allows physicians and their staff to access multiple HIT systems using a single user ID and ... systems can avoid building and maintaining multiple interfaces for every EMR in use by their ... health, rather than spending their time using multiple IT systems to share and exchange health care ...

Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology

... patients with relapsed and refractory multiple myeloma. Carfilzomib is the first in a new class ... Sundar Jagannath, M.D., Chief of the multiple Myeloma Program, Bone Marrow and Blood Stem Cell ... trials of carfilzomib in relapsed and refractory multiple myeloma patients during the Novel Therapies for ...

EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma

... administered orally once a day in patients with multiple myeloma who are refractory to other drug therapy. ... of ENMD-2076 alone and in combination in multiple myeloma were presented by Dr. Farag earlier ... ENMD-2076 was administered as a single agent in multiple myeloma models. Combination studies ...

MySignatureBook Certified Compliant With SAFE-BioPharma Digital Standard(TM)

... that enables companies to deploy and manage multiple types of credentials from a single ... and the ability to seamlessly integrate multiple Software as a Service (SaaS) applications in ... a web-based digital signing solution that gathers multiple signatures from a centrally managed, Web-based ...

GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C

... Several new antiviral drugs targeting multiple virus and host targets are currently ... suggest that combination therapies with multiple classes of drugs will be required to ... E partnered with GSK, the company is advancing multiple partnered and proprietary compounds designed ...
Other Contents
(Date:7/11/2014)... develop relationships with other group members to reduce aggression ... baboons the strategy for grooming activities shows a certain ... in the scientific journal Biology Letters . , ... not practiced without ulterior motives. To be groomed has ... while grooming another individual can provide access to infants, ...
(Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/11/2014)... In addition to the hippocampus, the marginal division ... and memory. What is the impact degree of ... learning and memory function? Yan Yu and his ... China found, using immunofluorescence staining, that substance P ... hippocampus and striatal marginal division of normal rats. ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
(Date:7/11/2014)... Oakland, CA (PRWEB) July 11, 2014 Ticket ... tickets at the Concord Pavilion . When it comes to ... from Luke Bryan. The 37-year-old Georgia native is one of the ... in the entertainment business. Bryan is currently out on his “That’s ... Among the many stops the tour will be making through the ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, ... exclusively to cell and gene therapies for cancer ... the organization as Senior Development Officer. , Corday ... securing gifts and addressing influential donors. Prior to ... for NewYork Presbyterian Hospital/Columbia University Medical Center, where ...
(Date:7/11/2014)... Global enterprises today are shifting towards the changing ... Managed services offer these global enterprises a strategic method ... into rising operational costs to companies. The aim to ... the global market driver for expanding the managed services ... market is estimated to grow from $142.75 billion in ...
(Date:7/11/2014)... July 11, 2014 Presently, disposable medical ... healthcare equipment and supplies segment. During the past two ... steady growth (on an average 12.5% per year), primarily ... settings. Currently, the US is the largest market for ... share of 40%. The second position is held by ...
(Date:7/11/2014)... Researchers from The Miriam Hospital have found that ... significantly higher rates of smoking than those without ... less likely to attempt quitting than those without ... be sufficient for this population. The study and ... print in the American Journal of Public ...
Breaking Medicine News(10 mins):Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Miriam Hospital study examines smoking prevalence 2
Other TagsOther Tags